Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (Nasdaq: NKTR) generates a steady flow of news tied to its role as a clinical-stage biotechnology company focused on autoimmune and chronic inflammatory diseases. Company announcements emphasize progress with its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), a regulatory T cell stimulator and IL-2 pathway agonist being evaluated in multiple mid-stage trials.
News coverage frequently highlights clinical data from the REZOLVE-AD Phase 2b study in moderate-to-severe atopic dermatitis and the REZOLVE-AA Phase 2b study in severe-to-very-severe alopecia areata. Press releases describe topline results, detailed efficacy and safety outcomes, and analyses in subgroups such as patients with atopic dermatitis and a history of asthma, including Asthma Control Questionnaire (ACQ-5) findings.
Investors and observers can also find updates on regulatory interactions, such as the U.S. Food and Drug Administration granting Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata. Additional news items cover Nektar’s participation in scientific and investor conferences, late-breaking oral presentations at major dermatology and allergy meetings, and corporate events like equity offerings and compliance updates related to its Nasdaq Capital Market listing.
This news page aggregates these disclosures so readers can follow developments in Nektar’s immunology pipeline, including rezpegaldesleukin and other programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. For those tracking NKTR stock or the evolution of Treg-focused therapies, this feed provides a centralized view of clinical milestones, financial communications and key corporate announcements.
Nektar Therapeutics (NASDAQ:NKTR) announced inducement equity grants on April 20, 2026 under its 2025 Inducement Plan. The Organization and Compensation Committee granted non-qualified stock options for 28,450 shares and 2,950 RSUs to six newly hired employees.
Options have an $100.35 exercise price, eight-year term, and standard four-year vesting; RSUs vest over four years with quarterly vesting after year one.
Nektar Therapeutics (Nasdaq: NKTR) will report first-quarter 2026 financial results on Thursday, May 7, 2026, after the U.S. market close. Howard Robin, president and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT to review results.
The live audio-only webcast and press release will be available via the company’s investor website. The web broadcast replay will remain available through June 7, 2026. Registrants will receive dial-in details and a PIN; pre-registration is required for call access.
Nektar Therapeutics (Nasdaq: NKTR) closed an underwritten public offering on April 23, 2026, raising approximately $373.8 million in gross proceeds.
The company sold 4,062,500 shares at $92.00 per share, including 529,891 shares issued upon full exercise of the underwriters' option. Joint bookrunners were Jefferies, TD Cowen, and Piper Sandler; Citigroup acted as bookrunner. The offering was made under a Form S-3ASR shelf registration effective November 12, 2025, and final prospectus materials are available via the SEC and the bookrunners listed.
Nektar Therapeutics (Nasdaq: NKTR) priced an upsized underwritten public offering of $325 million by selling 3,532,609 shares at $92.00 per share, with a 30‑day option to purchase up to 529,891 additional shares. The offering is expected to close on April 23, 2026.
Net proceeds are intended for general corporate purposes including research and development, clinical development (notably Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs. Jefferies, TD Cowen, Piper Sandler, and Citigroup are acting as bookrunners. The offering is made on a Form S-3ASR registration.
Nektar Therapeutics (Nasdaq: NKTR) has commenced a proposed underwritten public offering of $250,000,000 of common stock and, in lieu of common shares for certain investors, pre-funded warrants. Nektar may grant underwriters a 30-day option to purchase up to an additional $37,500,000 of common stock.
Proceeds are intended for general corporate purposes, including R&D and Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata. The offering is subject to market conditions and may not be completed as proposed.
Nektar Therapeutics (Nasdaq: NKTR) reported 52-week topline results from a 16-week blinded extension of the Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata. Continued twice-monthly dosing increased responder rates (SALT≤20, SALT30, SALT50) with a favorable safety profile and 94% completion.
Low-dose and high-dose arms reached 25.8% and 27.6% SALT≤20 at week 52 versus 6.7% placebo (p=0.049); safety remained mostly mild-to-moderate TEAEs.
Nektar (Nasdaq: NKTR) will host an investor call and live webcast on April 20, 2026 at 8:00 am ET / 5:00 am PT to review 52-week topline results from the 16-week extension treatment period of the Phase 2b REZOLVE-AA study of rezpegaldesleukin for severe-to-very-severe alopecia areata.
The company will issue a morning press release, present slides during the webcast, and post the materials and a replay on its investor events page for at least 30 days.
Nektar Therapeutics (Nasdaq:NKTR) presented Phase 2b and Phase 2b/extension data for rezpegaldesleukin at AAD 2026 showing efficacy across moderate-to-severe atopic dermatitis and activity in alopecia areata.
In REZOLVE-AD (393 patients) rezpegaldesleukin produced consistent mean EASI improvement and comparable EASI-75/90 responses across baseline vIGA-AD severity and regions. A Phase 3 ZENITH-AD program is planned to start in Q2 2026. In alopecia areata, high-dose rezpegaldesleukin showed greater SALT reduction versus placebo, with statistical significance achieved under specified exclusions; safety was consistent and well tolerated.
Nektar Therapeutics (Nasdaq:NKTR) announced that Phase 2b data for rezpegaldesleukin will be presented orally at the 2026 American Academy of Dermatology Annual Meeting, March 27-31, 2026, in Denver.
Two presentations on March 28 cover 36-week efficacy and safety in severe-to-very-severe alopecia areata and severity-dependent results in moderate-to-severe atopic dermatitis.
Nektar Therapeutics (Nasdaq: NKTR) reported Q4 and full-year 2025 results on March 12, 2026. Cash and investments were $245.8M at Dec 31, 2025, excluding ~$432M net proceeds from a Feb 2026 secondary and $44M from ATM sales.
Revenue fell to $55.2M in 2025 from $98.4M in 2024; 2025 net loss was $164.1M or $9.73 per share. Rezpegaldesleukin Phase 2 data supported a planned Phase 3 start in June 2026.